Kroll V M, Nothofer B, Werdermann K
Asthma-Krankenhaus, Kamillianer, Mönchengladbach.
Fortschr Med. 1993 Feb 20;111(5):76-8.
To test the efficacy and tolerability of loratadin, a new anthihistaminic agent in allergic bronchial asthma administered as adjunctive treatment in persistent asthma.
Eight-week open clinical trial. The 25 ambulatory patients retained existing treatment for asthma during the duration of the study. A two-week period of observation without the drug under investigation was followed by a six-week therapeutic phase, during which a single daily dose of 10 mg loratadine was taken. H1 antihistaminics, DNCG, ketotifene and systemic corticoids were not permitted. To monitor the therapeutic effect, the lung function parameters (VC, FEV1, peak flow, resistance) and the symptom score were established.
In comparison with the results of lung function testing during the pre-phase, the loratadine phase improved the parameters by up to 21%. The number of apneic events recorded in the patient's diary decreased by about 52%, the attacks of coughing diminished in the evaluation score from 8.5 to 3.0. For the rest, a significant decrease in the consumption of inhalative sympathomimetics was noted. In the overall assessment, 71% of the patients noted a good therapeutic response.
The results of this study show that loratadine, employed as an adjuvant therapeutic agent for the treatment of allergic bronchial asthma has a positive effect on symptomatology.
测试氯雷他定（一种新型抗组胺药）作为持续性哮喘辅助治疗药物在过敏性支气管哮喘中的疗效和耐受性。
为期八周的开放临床试验。25名门诊患者在研究期间维持现有的哮喘治疗方案。在为期两周的无研究药物观察期后，进入为期六周的治疗阶段，在此期间每日单次服用10毫克氯雷他定。不允许使用H1抗组胺药、二硝基氯苯、酮替芬和全身用皮质类固醇。为监测治疗效果，测定了肺功能参数（肺活量、第一秒用力呼气量、峰值流速、阻力）和症状评分。
与治疗前阶段的肺功能测试结果相比，氯雷他定治疗阶段的参数改善高达21%。患者日记中记录的呼吸暂停事件数量减少了约52%，咳嗽发作的评估评分从8.5降至3.0。此外，吸入性拟交感神经药的用量显著减少。总体评估中，71%的患者显示出良好的治疗反应。
本研究结果表明，氯雷他定作为过敏性支气管哮喘的辅助治疗药物，对症状学有积极影响。
